Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

Journal of Clinical Oncology

Volumn 23, Issue 18, 2005, Pages 4152-4161

  Banerji, Udai ^a   O'Donnell, Anne ^a   Scurr, Michelle ^a   Pacey, Simon ^a   Stapleton, Sarah ^a   Asad, Yasmin ^a   Simmons, Laura ^a   Maloney, Alison ^a   Raynaud, Florence ^a   Campbell, Maeli ^a   Walton, Michael ^a   Lakhani, Sunil ^a   Kaye, Stanley ^a   Workman, Paul ^a   Judson, Ian ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 AMINO 17 DEMETHOXYGELDANAMYCIN; ANTIHISTAMINIC AGENT; CYCLIN DEPENDENT KINASE 4; DRUG METABOLITE; GRANISETRON; HEAT SHOCK PROTEIN 70; PROTEIN C RAF 1; PROTEIN KINASE; STEROID; UNCLASSIFIED DRUG; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; DRUG DERIVATIVE; MACROCYCLIC LACTAM; RIFABUTIN;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERSENSITIVITY; KIDNEY CANCER; LEUKOCYTE; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; PANCREAS CANCER; PAROTID GLAND CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN INDUCTION; RECOMMENDED DRUG DOSE; SARCOMA; SIDE EFFECT; TASTE DISORDER; TUMOR BIOPSY; VOMITING; DOSE RESPONSE; DRUG ADMINISTRATION; ENZYME IMMUNOASSAY; MIDDLE AGED; NEOPLASM; TREATMENT OUTCOME; WESTERN BLOTTING;

ADULT; AGED; BENZOQUINONES; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LACTAMS, MACROCYCLIC; MALE; MIDDLE AGED; NEOPLASMS; RIFABUTIN; TREATMENT OUTCOME;

EID: 23044441106     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.00.612     Document Type: Article

References (29)

1. Maloney A, Workman P: HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther 2:3-24, 2002
2. Smith DF, Whitesall L, Nair SC, et al: Progesterone receptor structure and function altered by geldanamcyin, an hsp90 binding agent. Mol Cell Biol 15:6805-6812, 1995
3. Fang Y, Fliss AE, Robins DM, et al: Hsp90 regulates androgen hormone receptor hormone binding affinity. J Biol Chem 271:28697-28702, 1996
4. Xu W, Mimnaugh E, Rosser MF, et al: Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276:3702-3708, 2001
5. Nimmanpalli R, O'Brayan E, Bhalla K: Geldanamycin and its analogue 17-allylamino-17demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis an differentiation of Bcr-Abl positive human leukemic blasts. Cancer Res 61:1799-1804, 2001
6. Schulte TW, Blagosklony MV, Romanova L, et al: Destabilization of c-Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 16:5839-5845, 1996
7. Sato S, Fujita N, Tsuruo T, et al: Modulation of AKT kinase activity by binding to HSP90. Proc Natl Acad Sci U S A 97:10832-10837, 2000
8. Stepenova L, Leng X, Parker SB, et al: Mammalian p50cdc37 is a protein kinase targeting subunit of Hsp90 that binds and stabilizes cdk4. Genes Dev 10:1491-1502, 1996
9. Whitesell L, Sutphin PD, Pulcine EJ, et al: The physical association of multiple chaperone proteins with mutant p53 is altered by geldanamycin, a hsp90-binding agent. Mol Cell Biol 18:1517-1524, 1998
10. Forsythe HL, Jarivs JL, Turner JW, et al: Stable association of hsp90 and p23, but not hsp70, with active human telomerase. J Biol Chem 276:15571-15574, 2001
11. Prodromou C, Panaretou B, Chohan S, et al: The ATPase cycle of Hsp90 drives a molecular clamp via transient dimerization of the N-terminal domains. EMBO J 19:4383-4392, 2000
12. Shulte TW, An WG, Neckers LM: Geldanamycin induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun 239:655-659, 1997
13. Prodromou C, Pearl L: Structure and functional relationships of hsp90. Curr Canc Drug Targets 3:301-323, 2003
14. Supko JG, Hickman RL, Grever MR, et al: Preclinical pharmacological evaluation of geldanamycin as an anti-tumor agent. Canc Chemother and Pharmacol 36:305-312, 1995
15. Sausville EA, Tomaszewski JE, Ivy P: Clinical Development of 17-Allylamino, 17-Demthoxygeldanamycin. Curr Canc Drug Targets 3:377-383, 2003
16. Hostein I, Robertson D, Distefano F, et al: Inhibition of the signal transduction by the Hsp90 inhibitor 17-allylamino,17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61:4003-4009, 2001
17. Munster P, Basso A, Solit D, et al: Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in RB- and schedule-dependent manner. Clin Canc Res 7:2228-2236, 2001
18. Solit D, Zeng FF, Drobnjak M, et al: 17-Allylamino-17 demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/Neu and inhibits growth of prostate cancer xenografts. Clin Canc Res 8:986-993, 2002
19. Kelland LR, Sharp SW, Rogers PM: DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. JNCI 91:1940-1949, 1999
20. Shah VP, Midha KK, Findlay JW, et al: Bioanalytical method validation-A revisit with a decade of progress. Pharm Res 17:1551-1557, 2000
21. Banerji U, Walton M, Raynaud F, et al: Validation of pharmacodynamic endpoints for the HSP90 molecular chaperone inhibitor 17-allylamino 17-demethoxygeldanamycin (17AAG) in a human tumor xenograft model. Proc Am Assoc Canc Res 42:4473, 2001
22. Santos NC, Figueria-Coelho J, Martin-Silva J, et al: Multidisciplinary utilization of dimethyl sulfoxide: Pharmacological, cellular and molecular aspects. Biochem Pharmacol 65:1035-1041, 2003
23. Hidalgo M, Aylesworth C, Hammond LA, et al: Phase I and pharmacokinetic study of BMS-184476: A taxane with greater potency and solubility than paclitaxel. J Clin Oncol 19:2493-2503, 2001
24. Zuylen LV, Verweij J, Sparreboom A: Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19:125-141, 2001
25. Egorin MJ, Rosen DM, Wolff JH, et al: Metabolism of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58:2385-2396, 1998
26. Egorin MJ, Zuhowski EG, Rosen DM, et al: Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxy geldanamycin (NSC330507) in CD2F1 mice. Cancer Chemother Pharmacol 47:291-302, 2001
27. Clarke PA, Hostien I, Banerji U, et al: Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the Hsp90 molecular chaperone. Oncogene 19:4125-4133, 2000
28. Agnew E, Wilson RH, Morrison G, et al: Clinical pharmacokinetics of 17 Allylamino-17 demethoxy geldanamycin and the active metabolite 17 Amino demethoxy geldanamycin given as an one hour infusion daily for 5 days. Proc Am Assoc Cancer Res 43:272, 2002
29. Dymock B, Drysdale M, McDonald E, et al: Inhibitors of HSP90 and other chaperones for the treatment of cancer. Expert Opin Ther Patents 14:837-847, 2004